The stock of Myriad Genetics, Inc (MYGN) has gone down by -10.02% for the week, with a -33.53% drop in the past month and a -43.58% drop in the past quarter. The volatility ratio for the week is 7.21%, and the volatility levels for the past 30 days are 5.47% for MYGN. The simple moving average for the last 20 days is -19.38% for MYGN stock, with a simple moving average of -32.69% for the last 200 days.
Is It Worth Investing in Myriad Genetics, Inc (NASDAQ: MYGN) Right Now?
The stock has a 36-month beta value of 1.89. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 9 as “hold,” and 3 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MYGN is 87.40M, and at present, short sellers hold a 5.13% of that float. On November 14, 2024, the average trading volume of MYGN was 734.81K shares.
MYGN) stock’s latest price update
Myriad Genetics, Inc (NASDAQ: MYGN) has seen a rise in its stock price by 0.76 in relation to its previous close of 15.78. However, the company has experienced a -10.02% decline in its stock price over the last five trading sessions. accesswire.com reported 2024-11-14 that NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. (“Myriad Genetics, Inc.”) (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
Analysts’ Opinion of MYGN
Many brokerage firms have already submitted their reports for MYGN stocks, with Morgan Stanley repeating the rating for MYGN by listing it as a “Equal-Weight.” The predicted price for MYGN in the upcoming period, according to Morgan Stanley is $32 based on the research report published on September 19, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see MYGN reach a price target of $35. The rating they have provided for MYGN stocks is “Overweight” according to the report published on August 28th, 2024.
Scotiabank gave a rating of “Sector Outperform” to MYGN, setting the target price at $29 in the report published on June 27th of the current year.
MYGN Trading at -32.81% from the 50-Day Moving Average
After a stumble in the market that brought MYGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.73% of loss for the given period.
Volatility was left at 5.47%, however, over the last 30 days, the volatility rate increased by 7.21%, as shares sank -32.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.70% lower at present.
During the last 5 trading sessions, MYGN fell by -10.30%, which changed the moving average for the period of 200-days by -25.90% in comparison to the 20-day moving average, which settled at $19.72. In addition, Myriad Genetics, Inc saw -16.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MYGN starting from DIAZ PAUL J, who sale 15,000 shares at the price of $22.93 back on Oct 11 ’24. After this action, DIAZ PAUL J now owns 962,378 shares of Myriad Genetics, Inc, valued at $343,950 using the latest closing price.
DIAZ PAUL J, the Officer of Myriad Genetics, Inc, proposed sale 15,000 shares at $22.93 during a trade that took place back on Oct 11 ’24, which means that DIAZ PAUL J is holding shares at $343,950 based on the most recent closing price.
Stock Fundamentals for MYGN
Current profitability levels for the company are sitting at:
- -0.46 for the present operating margin
- 0.69 for the gross margin
The net margin for Myriad Genetics, Inc stands at -0.47. The total capital return value is set at -0.18. Equity return is now at value -16.39, with -10.40 for asset returns.
Based on Myriad Genetics, Inc (MYGN), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.11. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -115.87.
Currently, EBITDA for the company is -67.8 million with net debt to EBITDA at -0.85. When we switch over and look at the enterprise to sales, we see a ratio of 4.2. The receivables turnover for the company is 3.26for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.90.
Conclusion
To sum up, Myriad Genetics, Inc (MYGN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
